Given the special role of APOE+ macrophages in influencing immunotherapy outcomes, as previously highlighted in a pan-cancer analysis 29, we conducted IHC to evaluate APOE expression in both ICB-resistant and ICB-responsive patients. This evidence concerns the gene APOE and cancer.